Nature's Sunshine (NATR) Q4 Earnings: What To Expect

Stock Story

Published Mar 11, 2024 03:00AM ET

Updated Mar 11, 2024 08:01AM ET

Nature's Sunshine (NATR) Q4 Earnings: What To Expect

Wellness products company Nature’s Sunshine Products (NASDAQ:NATR) will be reporting earnings tomorrow after market close. Here's what to look for.

Last quarter Nature's Sunshine reported revenues of $111.2 million, up 6.4% year on year, in line with analyst expectations. It was a strong quarter for the company, with a decent beat of analysts' earnings estimates.

Is Nature's Sunshine buy or sell heading into the earnings? Find out by reading the original article on StockStory.

This quarter analysts are expecting Nature's Sunshine's revenue to grow 8.1% year on year to $111.1 million, improving on the 12.9% year-over-year decline in revenue the company had recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.15 per share.

Majority of analysts covering the company have reconfirmed their estimates over the last thirty days, suggesting they are expecting the business to stay the course heading into the earnings. The company has a history of exceeding Wall St's expectations, beating revenue estimates every single time over the past two years on average by 5.7%.

Looking at Nature's Sunshine's peers in the personal care segment, some of them have already reported Q4 earnings results, giving us a hint of what we can expect. Inter Parfums (NASDAQ:IPAR) delivered top-line growth of 5.8% year on year, beating analyst estimates by 1.5% and Edgewell Personal Care (NYSE:EPC) reported revenues up 4.2% year on year, exceeding estimates by 1.6%. Both stocks traded flat after the results (Inter Parfums and Edgewell Personal Care).

Read the full analysis of Inter Parfums's and Edgewell Personal Care's results on StockStory.

Investors in the personal care segment have had steady hands going into the earnings, with the stocks up on average 0.5% over the last month. Nature's Sunshine is down 6.9% during the same time, and is heading into the earnings with analyst price target of $21.5, compared to share price of $17.49.